Abstract

Due to the key role of tumor necrosis factor-alpha (TNF-α) in the pathogenesis of immunoinflammatory diseases, TNF-α inhibitors have been successfully developed and used in the clinical treatment of autoimmune disorders. Currently, five anti-TNF-α drugs have been approved: infliximab, adalimumab, golimumab, certolizumab pegol and etanercept. Anti-TNF-α biosimilars are also available for clinical use. Here, we will review the historical development as well as the present and potential future applications of anti-TNF-α therapies, which have led to major improvements for patients with several autoimmune diseases, such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn's disease (CD), ulcerative colitis (UC), psoriasis (PS) and chronic endogenous uveitis. Other therapeutic areas are under evaluation, including viral infections, e.g., COVID-19, as well as chronic neuropsychiatric disorders and certain forms of cancer. The search for biomarkers able to predict responsiveness to anti-TNF-α drugs is also discussed.

MeSH

Pharmaceutical Preparations, Tumor Necrosis Factor-Alpha, Therapeutics, Neoplasms, Covid-19

Cited by

• Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real-world finding. Immun Inflamm Dis, 2024
• Inflammatory Pathways to Carcinogenesis: Deciphering the Rheumatoid Arthritis-Lung Cancer Connection. Cancers (Basel), 2025
• Tumour necrosis factor-alpha inhibitors decrease mortality in COVID-19: a systematic review and meta-analysis. Crit Care, 2025
• Significant Associations Between Blood Cell Counts and Plasma Cytokines, Chemokines, and Growth Factors. Int J Mol Sci, 2025
• Apoptotic signaling by TNFR1 is inhibited by the α2-6 sialylation, but not α2-3 sialylation, of the TNFR1 N-glycans. J Biol Chem, 2025
• Psoriatic Arthritis: Pathogenesis and Targeted Therapies. Int J Mol Sci, 2023
• Anti-TNFα in inflammatory bowel disease: from originators to biosimilars. Front Pharmacol, 2024
• Cell-Based Therapeutic Strategies for Autoimmune Diseases. Immunotargets Ther, 2025
• Proteome-wide Mendelian randomization identifies therapeutic targets for ankylosing spondylitis. Front Immunol, 2024
• Cardiovascular Adverse Events Associated with Tumor Necrosis Factor-Alpha Inhibitors: A Real-World Pharmacovigilance Analysis. J Atheroscler Thromb, 2024
• The role of cell death in SARS-CoV-2 infection. Signal Transduct Target Ther, 2023
• Toll-like Receptor Gene Polymorphisms as Predictive Biomarkers for Response to Infliximab in Japanese Patients with Crohn's Disease. Diagnostics (Basel), 2025
• Progress in macrophage immune regulation of atherosclerosis. Am J Transl Res, 2025
• Epigallocatechin -3- gallate mitigates diazinon neurotoxicity via suppression of pro-inflammatory genes and upregulation of antioxidant pathways. BMC Neurosci, 2025
• Network pharmacology combined with molecular docking and experimental validation to explore the potential mechanism of against ankylosing spondylitis. Ann Med, 2023
• Myeloid deletion attenuates CFA-induced inflammation and pain in mice via ameliorating macrophage infiltration and inflammatory cytokine production. Front Immunol, 2023
• TNF‑α induces premature senescence in tendon stem cells via the NF‑κB and p53/p21/cyclin E/CDK2 signaling pathways. Int J Mol Med, 2025
• Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development. Antibodies (Basel), 2024
• Food allergens in immune systems. Food Sci Biotechnol, 2025
• Adrenomedullin-RAMP2 System Modulates Inflammation and Tissue Repair in Experimental Autoimmune Uveitis Via T-Cell and M2 Macrophage Regulation. Invest Ophthalmol Vis Sci, 2025